Eagle Global Advisors LLC Sells 240 Shares of Novo Nordisk A/S (NYSE:NVO)

Eagle Global Advisors LLC reduced its stake in Novo Nordisk A/S (NYSE:NVOFree Report) by 0.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 125,715 shares of the company’s stock after selling 240 shares during the period. Eagle Global Advisors LLC’s holdings in Novo Nordisk A/S were worth $13,005,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. CNB Bank bought a new stake in Novo Nordisk A/S during the fourth quarter valued at $26,000. Pacific Center for Financial Services boosted its stake in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Valued Wealth Advisors LLC bought a new stake in Novo Nordisk A/S during the fourth quarter valued at $28,000. Bell Investment Advisors Inc boosted its stake in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the period. Finally, Tyler Stone Wealth Management lifted its stake in Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Check Out Our Latest Stock Report on Novo Nordisk A/S

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded up $0.45 during trading on Friday, reaching $136.02. The company had a trading volume of 2,844,168 shares, compared to its average volume of 4,650,768. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The firm’s 50-day simple moving average is $128.13 and its 200 day simple moving average is $116.20. The firm has a market capitalization of $610.39 billion, a price-to-earnings ratio of 46.94, a price-to-earnings-growth ratio of 1.38 and a beta of 0.43. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The business had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.43 earnings per share for the current fiscal year.

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.